Mirum Pharmaceuticals, Inc. (MIRM) News
Follow Mirum Pharmaceuticals, Inc. (MIRM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 38 public stories across 19 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
MIRM Reports Fiscal Q3 Net Loss
MIRM reported a net loss attributable to shareholders for fiscal Q3 2026, down 4,993.56% year over year. Basic EPS was negative.
EQUITY | Nov 04, 2026, 06:47 AM UTC
M
Mirum Pharmaceuticals Reports Third-Quarter 2026 Financial Results
Mirum reported third-quarter 2026 financial results and provided a business update. The supplied text also mentions ATEBRIOZ approval and launch and positive Phase 3 results, but ends before giving further details.
EQUITY | Nov 03, 2026, 09:28 PM UTC
M
Mirum Pharmaceuticals Q3 Product Sales Total $185.721 Million
EARNINGS | Nov 03, 2026, 09:12 PM UTC
M
Mirum Pharmaceuticals Reports Q3 Operating Income
EARNINGS | Nov 03, 2026, 09:12 PM UTC
L
Mirum Pharmaceuticals Q3 Net Income: USD -40.766 Million
EARNINGS | Nov 03, 2026, 09:02 PM UTC
M
Mirum Raises 2026 Sales Guidance to $715M-$720M
Mirum raised its full-year 2026 net product sales guidance to $715M-$720M.
EARNINGS | Nov 03, 2026, 09:01 PM UTC
M
Mirum Pharmaceuticals’ Phase 3 EXPAND Meets Primary Endpoint
Mirum Pharmaceuticals said LIVMARLI met the primary endpoint and key secondary endpoints in the Phase 3 EXPAND trial for cholestatic pruritus. The company plans to submit a U.S. supplemental NDA in the first half of 2027
EQUITY | Oct 13, 2026, 12:13 PM UTC
M
Mirum Shares Rise 3.3% After Livmarli Meets Phase 3 Primary Endpoint
Mirum Pharmaceuticals said Livmarli (maralixibat) met the primary endpoint in a trial treating cholestatic pruritus in certain patients with liver diseases. Shares rose 3.3% to $61.05 in premarket trading Monday.
EQUITY | Oct 12, 2026, 01:17 PM UTC
M
Mirum Phase 3 EXPAND Study Meets Primary and All Five Secondary Endpoints
Mirum reported that its Phase 3 EXPAND study of LIVMARLI met the primary itch endpoint and all five secondary endpoints, with no new safety signals. The company plans to file a U.S. sNDA in H1 2027.
EQUITY | Oct 12, 2026, 12:28 PM UTC
M
Mirum Says LIVMARLI Phase 3 EXPAND Study Met Primary Endpoint
Mirum Pharmaceuticals announced topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) in patients with ultra-rare cholestatic liver diseases, reporting that the primary endpoint was met.
EQUITY | Oct 12, 2026, 12:00 PM UTC
L
Mirum Pharmaceuticals Is Maintained at Buy by Citigroup
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 06:07 PM UTC
L
Mirum Pharmaceuticals Is Maintained at Outperform by Baird
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 12:03 PM UTC
L
Mirum Pharmaceuticals Price Target Raised to $195.00/Share From $140.00 by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 05:03 PM UTC
L
HC Wainwright & Co. maintains Buy rating on Mirum Pharmaceuticals, $195 price target
HC Wainwright & Co. maintained their Buy rating on Mirum Pharmaceuticals's stock with a price target of $195.00.The price target implies an upside of 117.4% from the Sep 25 close of $89.70.Key takeaways from the analyst
EQUITY | Sep 28, 2026, 04:53 PM UTC
L
Mirum's liver infection drug lowers virus levels in late-stage study
By Sneha S KMirum Pharmaceuticals NASDAQ:MIRM on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study.Here are some key details
NEWS | Sep 28, 2026, 03:23 PM UTC
L
Mirum Pharmaceuticals gets FDA approval for Atebrioz; brelovitug Phase 3 AZURE-1 meets primary endpoint
Mirum Pharmaceuticals announced FDA approval of Atebrioz for reducing new heterotopic ossification in patients 12 and older and reported positive Phase 3 AZURE-1 topline results for brelovitug in chronic hepatitis delta.
REGULATION | Sep 28, 2026, 12:16 PM UTC
L
Mirum Pharmaceuticals, Inc. (MIRM) Phase 3 AZURE-1 Meets Primary Endpoint in HDV
Mirum said brelovitug met the primary endpoint at Week 24 in Phase 3 AZURE-1 for chronic HDV, with 56% (300 mg QW) and 45% (900 mg Q4W) responders vs 0% delayed (p<0.0001). Phase 2b showed deeper viral suppression and hi
NEWS | Sep 28, 2026, 12:01 PM UTC
L
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully human mo
NEWS | Sep 28, 2026, 12:01 PM UTC
L
Weekly Recap: Atebrioz FDA approval and $561.3M cash for Zilurgisertib
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) won FDA approval for Atebrioz for FOP patients 12+, paving the way for an October 2026 U.S. launch and patient access program, while holding $561.3M to fund Zilurgisertib and pre
REGULATION | Sep 28, 2026, 11:06 AM UTC
L
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the
NEWS | Sep 27, 2026, 09:00 PM UTC
L
Mirum Pharmaceuticals, Inc. (MIRM) Wins FDA Nod for Atebrioz in FOP
The FDA approved Atebrioz (zilurgisertib) tablets to reduce total new heterotopic ossification in FOP patients aged 12+, licensed by Incyte to Mirum. A Rare Pediatric Disease PRV was issued to Incyte.Material DetailsCont
REGULATION | Sep 25, 2026, 11:01 PM UTC
L
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterot
REGULATION | Sep 25, 2026, 11:00 PM UTC
L
US FDA approves Mirum's drug for rare bone disorder
The US Food and Drug Administration has approved Mirum Pharmaceuticals' NASDAQ:MIRM drug to treat a rare bone disorder, the regulator said on Friday.
REGULATION | Sep 25, 2026, 06:57 PM UTC
L
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
Shares of Incyte (INCY) and Mirum Pharmaceuticals (MIRM) both eased on Friday after opening higher as traders waited for a weekend ruling from U.S. regulators on their shared rare-disease pill zilurgisertib.INCY opened u
REGULATION | Sep 25, 2026, 06:44 PM UTC
H
MIRM: Commercial growth, pipeline catalysts, and global expansion position the business for continued momentum
Strong Q2 revenue and raised guidance reflect robust commercial growth, especially for LIVMARLI in rare liver diseases. Multiple near-term clinical milestones, commercial team expansion, and international growth are expe
EARNINGS | Sep 15, 2026, 02:07 PM UTC
H
MIRM: Strong Q2 revenue, pipeline catalysts, and global expansion set the stage for continued growth
Q2 revenue reached $176.2 million, prompting raised full-year guidance. LIVMARLI's growth is driven by PFIC expansion and international rollout, while multiple pivotal data readouts and a PDUFA date for zilurgisertib are
EARNINGS | Sep 15, 2026, 01:41 PM UTC
L
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on September 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non
EQUITY | Sep 14, 2026, 08:01 PM UTC
L
MIRM: Pivotal data and regulatory milestones across rare diseases set the stage for significant growth
Upcoming quarters will see pivotal data readouts for HDV, cholestatic pruritus, and FOP, with regulatory submissions and potential label expansions planned for next year. Market opportunities are expanding through improv
EQUITY | Sep 10, 2026, 03:01 PM UTC
L
MIRM: Multiple late-stage catalysts and commercial expansion set the stage for significant financial growth
A diversified rare disease portfolio is driving strong commercial growth, with multiple near-term clinical and regulatory catalysts expected. LIVMARLI expansion, new launches, and pipeline progress position the business
EQUITY | Sep 09, 2026, 04:22 PM UTC
M
MIRM sees near-term clinical catalysts and LIVMARLI expansion efforts
TradingView News discussion points to a diversified rare-disease portfolio, strong commercial growth, regulatory progress for volixibat and brelovitug, and efforts to expand LIVMARLI’s reach.
EQUITY | Sep 09, 2026, 03:45 PM UTC
L
Mirum Pharmaceuticals appoints Rob Myers as Chief Medical Officer
Mirum Pharmaceuticals (MIRM) appointed Rob Myers, M.D., as Chief Medical Officer, effective September 21, 2026. He will join the leadership team and lead the company’s global medical and clinical development function.
EQUITY | Sep 08, 2026, 12:30 PM UTC
L
MIRUM to participate in upcoming investor conferences
Mirum Pharmaceuticals (Nasdaq: MIRM) announced it will participate in upcoming investor conferences, with selected fireside chats webcast live via its Investors section. An archive will be available.
EQUITY | Sep 02, 2026, 08:01 PM UTC
L
Mirim Pharmaceuticals price target held at $137 by Citizens
Citizens maintained a $137.00-per-share price target for Mirum Pharmaceuticals.
EQUITY | Aug 27, 2026, 02:12 PM UTC
L
MIRM Raises FY26 Guide To $680-700m
MIRM raises FY26 sales guide
EARNINGS | Aug 05, 2026, 08:12 PM UTC
L
Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $660.000M-$680.000M to $680.000M-$700.000M vs $675.249M Est
Mirum Pharmaceuticals (NASDAQ: MIRM ) raises FY2026 sales outlook from $660.000 million-$680.000 million to $680.000 million-$700.000 million vs $675.249 million estimate.
EARNINGS | Aug 05, 2026, 08:04 PM UTC
L
Mirum treatment of primary sclerosing cholangitis granted FDA orphan status
Mirum...
EQUITY | Jul 21, 2026, 06:00 PM UTC
L
Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing
() -- Eric Bjerkholt, CFO, on July 06, 2026, sold 5,000 shares in Mirum Pharmaceuticals (MIRM) for $611,273. Following the Form 4 filing with the SEC, Bjerkholt has control over a total of 42,181 common shares of the com
REGULATION | Jul 08, 2026, 09:13 PM UTC
L
JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125
JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ: MIRM ) with a Overweight and raises the price target from $115 to $125.
EQUITY | Jul 02, 2026, 02:30 PM UTC